Results 51 to 60 of about 1,361 (136)

Supplementary Figure S3 from Combined Aurora Kinase A (AURKA) and WEE1 Inhibition Demonstrates Synergistic Antitumor Effect in Squamous Cell Carcinoma of the Head and Neck

, 2019
Supplementary Figure S3 related to Figure 5A-C. (A) Individual tumor volume changes in FaDu-xenografted mice treated with vehicle, adavosertib (30 mg/kg or 90 mg/kg, daily, p.o.), alisertib (30 mg/kg, daily, p.o.), or the combinations of alisertib with ...
Jeffrey P. Townsend (14963915), Dong-hua Yang (15012759), Ja Seok Koo (14888484), Kyung Jin Eoh (8568471), Wendell G. Yarbrough (232305), Janaki Parameswaran (15012753), Erica A. Golemis (14949004), Natalia Issaeva (839371), Stephen G. Gaffney (15012762), Ilya G. Serebriiskii (14893961), Barbara Burtness (550227), Jong Woo Lee (360063), Fang Zhu (185566), Ranee Mehra (5707862), Teresa Sandoval-Schaefer (15012756), Roshan Sharma (5904719), Elizabeth B. Perry (14920176)   +16 more
core   +1 more source

Supplementary Figure S4 from Combined Aurora Kinase A (AURKA) and WEE1 Inhibition Demonstrates Synergistic Antitumor Effect in Squamous Cell Carcinoma of the Head and Neck

, 2019
Supplementary Figure S4 related to Figure 5D-F. (A) Individual tumor volume changes in Detroit 562-xenografted mice treated with vehicle, adavosertib (30 mg/kg, daily, p.o.), alisertib (30 mg/kg, daily, p.o.), or the combinations of alisertib with ...
Jeffrey P. Townsend (14963915), Dong-hua Yang (15012759), Ja Seok Koo (14888484), Kyung Jin Eoh (8568471), Wendell G. Yarbrough (232305), Janaki Parameswaran (15012753), Erica A. Golemis (14949004), Natalia Issaeva (839371), Stephen G. Gaffney (15012762), Ilya G. Serebriiskii (14893961), Barbara Burtness (550227), Jong Woo Lee (360063), Fang Zhu (185566), Ranee Mehra (5707862), Teresa Sandoval-Schaefer (15012756), Roshan Sharma (5904719), Elizabeth B. Perry (14920176)   +16 more
core   +1 more source

Phase I/II Study of the WEE1 Inhibitor Adavosertib (AZD1775) in Combination with Carboplatin in Children with Advanced Malignancies: Arm C of the AcSé-ESMART Trial

International audienceAbstract Purpose: AcSé-ESMART Arm C aimed to define the recommended dose and activity of the WEE1 inhibitor adavosertib in combination with carboplatin in children and young adults with molecularly enriched recurrent/refractory ...
Abbou, Samuel, Paoletti, Xavier, Defachelles, Anne, Sophie, Miah, Kowser, André, Nicolas, Hübschmann, Daniel, Defachelles, Anne Sophie, Mortimer, Peter G.S., Harttrampf, Anne C, Deloger, Marc, Marshall, Lynley, V, Aerts, Isabelle, Bautista, Francisco, Brard, Caroline, Gatz, Susanne, A, de Carli, Emilie, Rubino, Jonathan, Thebaud, Estelle, Marshall, Lynley V, Mortimer, Peter G S, Gatz, Susanne A; id_orcid, Rondof, Windy, Harttrampf, Anne, C, Rübsam, Marc, Godin, Robert, Vassal, Gilles, Geoerger, Birgit, Nebchi, Souad   +27 more
core   +1 more source

Design Space Visualization and Technoeconomic Evaluation of a Batch Manufacturing Process for the Green Production of an Anti-cancer Drug (Adavosertib) Precursor [PDF]

The development of cost-effective and sustainable manufacturing processes is a growing priority in the pharmaceutical industry, with many companies turning to computational modeling to reduce reliance on experimental campaigns.
Cox, Robert J., Molaei Chalchooghi, Mazaher, Gerogiorgis, Dimitrios I., Blair, Matthew   +3 more
core   +1 more source

Combination AURKA and WEE1 Inhibition Exhibits Efficacy in EGFR or Pan-ERBB Inhibitor-Resistant Head and Neck Squamous Cell Carcinoma. [PDF]

Cancer Res Commun
Silva FN, Lee JW, Nguyen TT, Goeckel FM, Bagnyukova T, Borghaei H, Golemis EA, Burtness BA.   +7 more
europepmc   +1 more source

Phase II Study of Adavosertib in Patients With Tumors Containing BRCA1 and BRCA2 Mutations: Results From the NCI-MATCH ECOG-ACRIN Cancer Research Group (EAY131) Subprotocol Z1I. [PDF]

JCO Precis Oncol
Kummar S, Song Z, Reiss KA, Ford JM, Chen L, Rolig AS, Zwiebel JA, Gore SD, Gray RJ, Wang V, McShane LM, Rubinstein LV, Patton D, Gross J, Brunnquell D, Jackson LF, Williams PM, Hamilton SR, Takebe N, Brufsky A, Tricoli JV, Conley BA, Arteaga CL, Harris LN, O'Dwyer PJ, Chen AP, Flaherty KT.   +26 more
europepmc   +1 more source

Pharmacological WEE1 inhibition as a strategy to overcome cisplatin resistance in non-seminoma testicular cancer: insights from preclinical models. [PDF]

Sci Rep
Tamburello M, Boldini C, Abate A, Salvi V, Valcamonico F, Laganà M, Cosentini D, Suardi NR, Mirabella G, Altieri B, Sigala S.   +10 more
europepmc   +1 more source

Supplementary Figure S6 from Combination AURKA and WEE1 Inhibition Exhibits Efficacy in EGFR or Pan-ERBB Inhibitor–Resistant Head and Neck Squamous Cell Carcinoma

<p>Cell cycle and signaling changes induced by treatment with VIC-1911 and adavosertib in parental, AfaR, and ErlR HNSCC models.</p>
Hossein Borghaei, Jong Woo Lee, Erica A. Golemis, Fiona M. Goeckel, Barbara A. Burtness, Flaviane N. Silva, Theodore T. Nguyen, Tetyana Bagnyukova   +7 more
core   +1 more source

WEE1 kinase in cancer: Molecular mechanisms and inhibitor insights. [PDF]

EXCLI J
Kumar A, Paudel KR, Kaur R, Bhatia R.
europepmc   +1 more source

NN-01-195, a Novel Conjugate of HSP90 and AURKA Inhibitors, Effectively Targets Solid Tumors. [PDF]

Mol Cancer Ther
Nguyen TT, Nandwana NK, Srikanth YVV, Bagnyukova T, Chkhalo O, Cai KQ, Lamperelli J, Pirestani S, Mehra MK, Burtness BA, Borghaei H, Akunuri R, Cassel J, Lu L, Salvino JM, Golemis EA.   +15 more
europepmc   +1 more source